Your session is about to expire
← Back to Search
Radiation
177Lu-PSMA with Biopsy for Prostate Cancer
Phase 1
Recruiting
Led By Johannes Czernin
Research Sponsored by Jonsson Comprehensive Cancer Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Histologically confirmed prostate cancer
Evidence of lymph node or soft tissue metastatic disease amenable to image-guided biopsy based on positron emission tomography (PET)/computed tomography (CT) images
Must not have
Patients with significant congenital or acquired bleeding disorders (e.g. von Wildebrand's disease, acquired bleeding factor inhibitors) are not eligible
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights
No Placebo-Only Group
Summary
This trial studies how well a targeted radiation treatment works in patients with advanced prostate cancer that doesn't respond to hormone therapy. The treatment aims to kill cancer cells by delivering radiation directly to them.
Who is the study for?
This trial is for men with advanced prostate cancer that no longer responds to hormone therapy and has spread. Participants must have a confirmed diagnosis, be willing volunteers, eligible for 177Lu-PSMA treatment, and have metastatic disease suitable for biopsy. They need adequate blood clotting function and may need to stop certain medications like blood thinners before the biopsy.
What is being tested?
The study is examining how well a targeted radioactive drug therapy (177Lu-PSMA) works by using image-guided biopsies on tumors. The goal is to understand why some cancers resist this treatment and use this information to improve future therapies.
What are the potential side effects?
While not explicitly listed in the provided information, potential side effects of image-guided biopsies can include pain at the biopsy site, bleeding, infection risk, and reactions related to sedation or anesthesia used during the procedure.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
My prostate cancer diagnosis was confirmed through a tissue examination.
Select...
My scans show cancer spread to lymph nodes or tissues that can be biopsied.
Exclusion Criteria
You may be eligible for the trial if you check “No” for criteria below:Select...
I do not have a significant bleeding disorder.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ up to 5 years
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
Treatment Details
Awards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
1Treatment groups
Experimental Treatment
Group I: Diagnostic (image-guided biopsy)Experimental Treatment1 Intervention
Patients undergo an image-guided biopsy at baseline and 2-4 weeks after cycle 2 of 177Lu-PSMA-617 therapy.
Research Highlights
Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
177Lu-PSMA Radioligand Therapy targets prostate-specific membrane antigen (PSMA) expressed on prostate cancer cells, delivering targeted radiation to kill these cells while sparing surrounding healthy tissue. This precision reduces side effects and improves treatment efficacy.
Other common treatments include androgen deprivation therapy (ADT), which lowers testosterone levels to slow cancer growth, and chemotherapy, which uses drugs to kill rapidly dividing cells. Immunotherapy, such as sipuleucel-T, stimulates the immune system to attack cancer cells.
Understanding these mechanisms helps patients and doctors choose the most appropriate treatment based on the cancer's characteristics and patient health.
Biomarkers to personalize treatment with 177Lu-PSMA-617 in men with metastatic castration-resistant prostate cancer - a state of the art review.
Biomarkers to personalize treatment with 177Lu-PSMA-617 in men with metastatic castration-resistant prostate cancer - a state of the art review.
Find a Location
Who is running the clinical trial?
Jonsson Comprehensive Cancer CenterLead Sponsor
370 Previous Clinical Trials
35,097 Total Patients Enrolled
31 Trials studying Prostate Cancer
2,490 Patients Enrolled for Prostate Cancer
Johannes CzerninPrincipal InvestigatorUCLA / Jonsson Comprehensive Cancer Center
2 Previous Clinical Trials
400 Total Patients Enrolled
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- My prostate cancer diagnosis was confirmed through a tissue examination.I do not have a significant bleeding disorder.I can stop my blood thinners for a week before a biopsy, as agreed by my doctors.My scans show cancer spread to lymph nodes or tissues that can be biopsied.
Research Study Groups:
This trial has the following groups:- Group 1: Diagnostic (image-guided biopsy)
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.